There is a long-felt yet unmet need for effective treatments for pediatric medulloblastoma, a cancer caused by genetic alterations or loss of function of subunits of the SWI/SNF chromatin remodeling complex that result in EZH2-dependent oncogenesis. Researchers at the University of Colorado have developed a method of treating a medulloblastoma in a pediatric subject by administering an enhancer of a zeste homolog 2 (EZH2) inhibitor such as Tazemetostat to prevent and/or inhibit proliferation of a medulloblastoma cell.